Articles On Starpharma Holdings (ASX:SPL)

Shares in ASX biotech Starpharma Holdings Ltd (ASX: SPL) have hit a new 12-month high after the company announced positive news regarding one of its drug candidates. Novel cancer treatment being tested The company said in a statement...

Vitura Health says its acquired Doctors on Demand platform is gaining traction after a slow start New motoring laws will ‘drive’ medicinal cannabis demand, says Bioxyne All the latest cancer trial news you can use   While the jury is out...

Highlights Lithium and mining names dominate strong uptrends Tech and healthcare stocks add momentum to rallies Weakness persists across select consumer and industrial names ASX trends show strong momentum in mining and lithium st...

Highlights Uptrend stocks show strong momentum across sectors Retail and consumer names dominate downtrend list Technical signals highlight shifting market sentiment ASX trend scans reveal strong momentum in select sectors while r...

Highlights Mixed momentum patterns across ASX-listed companies Strength concentrated in selected resource and infrastructure names Softening trend structure in parts of technology and healthcare The latest ASX trend sc...

ASX healthcare share Starpharma Holdings Ltd (ASX: SPL) has rocketed 365% over the past 12 months. Had you put $10,000 into this ASX small-cap share in March 2025, your holdings would be worth $36,500 today. Starpharma is an Austr...

S&P/ASX All Ords Index (ASX: XAO) shares are 0.26% lower at 8,668.3 points on Friday. Today's fall builds on yesterday's 1.77% drop after missile strikes on energy assets in the Middle East caused a spike in oil prices. ASX All...

The S&P/ASX Small Ords Index (ASX: XSO) is down 0.1% on Friday but up 16% over the past 12 months. By comparison, the S&P/ASX All Ords Index (ASX: XAO) is up 0.07% today and has risen 11% over the past year. The Small Ords i...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

ASX stalwart Cryosite and newbie Vitrafy are having their day in the sun Neuren won’t take European knock-back lying down Entropy beds down its first cohort in its groundbreaking psychedelics trial   Investors are warming to the ASX-liste...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

Highlights Chart-based market scans highlighted varied participation across sectors. Multiple ASX-listed companies appeared across contrasting technical classifications. Index representation reflected broad equity market int...

Shares in drug developer Starpharma Ltd (ASX: SPL) have jumped more than 10% after the company's Chief Executive Officer said that interest in the company's technology was "particularly strong''. In its quarterly report released on Thur...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Knowing which ASX shares to avoid is just as important as knowing which ones to buy. After all, owning the wrong shares could hold back your portfolio returns and limit your wealth creation. With that in mind, let's take a look at three ASX...

Highlights Broad uptrend momentum seen across diverse sectors. Multiple companies experience renewed chart strength. Downtrend signals highlight shifting market sentiment. A comprehensive exploration of rising and weak...

HIGHLIGHTS Uptrending names include ANZ Group (ASX:ANZ), Liontown Resources (ASX:LTR) and Northern Star (ASX:NST). Downtrending names feature Technology One (ASX:TNE), JB Hi-Fi (ASX:JBH) and HMC Capital (ASX:HMC). Momentum s...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Optiscan Imaging led the biotech pack in October, while some of the Big Four stocks were late scratchings Does CSL have an iron deficiency? Weebit Nano ‘mini me’ Dorsavi quietly jockeys for position in the high-stakes chip race   The ASX...

After five months of consecutive gains, the ASX 200 fell 0.78% in September with nine of 11 sectors in the red Smaller companies performed strongly with the ASX Emerging Companies and ASX Small Ordinaries rising 13% and 3% respectively Emb...

Starpharma Holdings Ltd (ASX: SPL) shareholders are sitting on gains of more than 100% for the month after the company announced a new collaboration with Radiopharm Theranostics Ltd (ASX: RAD). The junior biotechnology company's stock wa...

Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain c...

Highlights Global indices surge as technology heavyweights strengthen momentum Commodities display resilience with gold and silver pushing higher Crypto sector under pressure while traditional assets gain traction Glob...

ASX lifts 0.43pc, now 2.69pc below 52-week high Materials leads gains, up 2.6pc as XGD rises 6.7pc Gains in iron ore and gold prices push resource stocks higher   ASX miners surge on gold and iron ore gains The ASX 200 rose 0.43% today, p...

Highlights Starpharma (ASX:SPL) headlines early gains with a key pharma collaboration RooLife Group (ASX:RLG) advances with major China market distribution deal Yandal Resources (ASX:YRL) impresses with strong drilling updat...

Shares in junior biotech company Starpharma Holdings Ltd (ASX: SPL) are up more than 63% after the firm announced a collaboration and license agreement with major drug company Genentech, which could lead to success payments of up to US$564...

Starpharma Holdings (ASX: SPL) has signed a collaboration and licence agreement with US-based company Genentech to develop innovative cancer therapies leveraging Starpharma’s proprietary DEP (dendrimer-enhanced product) drug delivery platfo...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

 Pro Medicus shares surge up to 7% on record revenue and earnings Tetratherix pockets $3.3 million, while Rhythm girds for a raising CEO oration inspires Starpharma share run   The $32 billion market cap ProMedicus (ASX:PME) has drawn the...

Commonwealth Bank shares fall 5pc on yearly results ASX falls from near all-time highs as sell down bites Weakness in utilities and major resource stocks undercuts resistance   CBA leads sell down Commonwealth Bank (ASX:CBA) lifted net pr...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Highlights ASX200 shows positive investor sentiment with recent gains. Penny stocks offer opportunities amidst market optimism. Highlight: Three resilient ASX penny stocks with robust financials. The Australian market has recently...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

In this interview Dale Gillham and small cap company director Rod North discuss what to look for in microcap stocks and what place they should have in an investor’s portfolio. They discuss success stories, risk vs reward, and, the challe...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Overview of Market Movements  As of 8:30 am AEST, ASX 200 futures have shown a modest increase of 4 points, representing a 0.05% rise. This slight upward movement reflects a cautious tone in the market as global investors digest the latest...

ASX healthcare shares Starpharma Holdings Ltd (ASX: SPL) and Mesoblast Ltd (ASX: MSB) are outgunning their peers today after the companies released positive news for shareholders. The Starpharma share price is up 3.41% to 9.1 cents afte...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

With Starpharma (ASX:SPL) shares having lost losing three-quarters of their value over the previous year when new CEO Cheryl Maley reported for duty on January 8 this year, the former big drug company exec knew that maintaining the status q...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Insider buying often signals confidence in a company's future, and a few cheap ASX shares have caught investor attention recently due to notable insider activity. This kind of buying activity can be a strong indicator of growth potentia...